论文部分内容阅读
目的：探讨口服溴隐亭和伽玛刀治疗垂体泌乳素腺瘤的临床疗效。方法：对３０ 例垂体泌乳素腺瘤患者，经口服溴隐亭或伽玛刀治疗前后的临床症状、血清泌乳素（ Ｐ Ｒ Ｌ） 水平、肿瘤体积等方面的改变进行了比较。结果：口服溴隐亭组，经治疗后其血清 Ｐ Ｒ Ｌ 水平降低优于伽玛刀组，两者有显著性差异（ Ｐ＜ ００１） ， 肿瘤体积缩小则伽玛刀组优于溴隐亭组（ Ｐ＜ ００１） 。结论：垂体泌乳素腺瘤患者口服溴隐亭近期疗效显著，伽玛刀治疗后症状改善不显著者加服溴隐亭仍有效，其远期疗效尚待进一步观察。
Objective: To investigate the clinical efficacy of oral bromocriptine and gamma knife in the treatment of pituitary prolactinoma. METHODS: Clinical symptoms, serum prolactin (PRL) levels, and tumor volumes before and after oral bromocriptine or gamma knife treatment were compared in 30 patients with pituitary prolactinoma. RESULTS: In the bromocriptine group after oral administration, the serum P R L level was lower than that of the gamma knife group after treatment. There was a significant difference between the two groups (P < 0 01). When the tumor volume was reduced, the gamma knife group was superior to bromine. Hiding group (P<001). Conclusion: The curative effect of oral bromocriptine in patients with pituitary prolactin adenoma is significant, and bromocriptine is still effective when gamma knife treatment is not significantly improved. The long-term efficacy of bromocriptine remains to be further observed.